{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T10:05:04Z","timestamp":1781690704902,"version":"3.54.5"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Natural Science Foundation of Hubei Province of China","award":["2025AFB368"],"award-info":[{"award-number":["2025AFB368"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-26340-2","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T13:35:50Z","timestamp":1764164150000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Post marketing safety surveillance of atezolizumab based on a retrospective analysis of the FDA adverse events reporting system (FAERS)"],"prefix":"10.1038","volume":"15","author":[{"given":"Gan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danfeng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunyan","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuhua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"26340_CR1","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s00262-020-02736-z","volume":"70","author":"D Kwapisz","year":"2021","unstructured":"Kwapisz, D. Pembrolizumab and atezolizumab in triple-negative breast cancer. Cancer Immunol. Immunother. 70, 607\u2013617. https:\/\/doi.org\/10.1007\/s00262-020-02736-z (2021).","journal-title":"Cancer Immunol. Immunother."},{"key":"26340_CR2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","volume":"389","author":"A Rittmeyer","year":"2017","unstructured":"Rittmeyer, A. et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389, 255\u2013265. https:\/\/doi.org\/10.1016\/S0140-6736(16)32517-X (2017).","journal-title":"Lancet"},{"key":"26340_CR3","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.annonc.2023.07.001","volume":"34","author":"E Felip","year":"2023","unstructured":"Felip, E. et al. Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): A randomised, multicentre, open-label, phase III trial. Ann. Oncol. 34, 907\u2013919. https:\/\/doi.org\/10.1016\/j.annonc.2023.07.001 (2023).","journal-title":"Ann. Oncol."},{"key":"26340_CR4","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/s41591-022-01868-2","volume":"28","author":"AX Zhu","year":"2022","unstructured":"Zhu, A. X. et al. Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma. Nat. Med. 28, 1599\u20131611. https:\/\/doi.org\/10.1038\/s41591-022-01868-2 (2022).","journal-title":"Nat. Med."},{"key":"26340_CR5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.eururo.2023.03.013","volume":"84","author":"M Roupret","year":"2023","unstructured":"Roupret, M. et al. European association of urology guidelines on upper urinary tract urothelial carcinoma: 2023 Update. Eur. Urol. 84, 49\u201364. https:\/\/doi.org\/10.1016\/j.eururo.2023.03.013 (2023).","journal-title":"Eur. Urol."},{"key":"26340_CR6","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s40264-021-01086-8","volume":"44","author":"A Mascolo","year":"2021","unstructured":"Mascolo, A. et al. Immune checkpoint inhibitors and cardiotoxicity: An analysis of spontaneous reports in eudravigilance. Drug Saf. 44, 957\u2013971. https:\/\/doi.org\/10.1007\/s40264-021-01086-8 (2021).","journal-title":"Drug Saf."},{"key":"26340_CR7","doi-asserted-by":"publisher","first-page":"1134436","DOI":"10.3389\/fimmu.2023.1134436","volume":"14","author":"R Ruggiero","year":"2023","unstructured":"Ruggiero, R. et al. Do peripheral neuropathies differ among immune checkpoint inhibitors? Reports from the European post-marketing surveillance database in the past 10 years. Front. Immunol. 14, 1134436. https:\/\/doi.org\/10.3389\/fimmu.2023.1134436 (2023).","journal-title":"Front. Immunol."},{"key":"26340_CR8","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/S0140-6736(23)01796-8","volume":"402","author":"S Qin","year":"2023","unstructured":"Qin, S. et al. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): A randomised, open-label, multicentre, phase 3 trial. Lancet 402, 1835\u20131847. https:\/\/doi.org\/10.1016\/S0140-6736(23)01796-8 (2023).","journal-title":"Lancet"},{"key":"26340_CR9","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2024.2438749","author":"H Wen","year":"2024","unstructured":"Wen, H., Lei, Y. & Mao, L. Post-marketing safety of panitumumab: A real-world pharmacovigilance study. Expert Opin. Drug Saf. https:\/\/doi.org\/10.1080\/14740338.2024.2438749 (2024).","journal-title":"Expert Opin. Drug Saf."},{"key":"26340_CR10","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1111\/jep.12184","volume":"20","author":"P Baldo","year":"2014","unstructured":"Baldo, P. & De Paoli, P. Pharmacovigilance in oncology: Evaluation of current practice and future perspectives. J. Eval. Clin. Pract. 20, 559\u2013569. https:\/\/doi.org\/10.1111\/jep.12184 (2014).","journal-title":"J. Eval. Clin. Pract."},{"key":"26340_CR11","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1080\/14740338.2022.2131770","volume":"21","author":"D Arku","year":"2022","unstructured":"Arku, D., Yousef, C. & Abraham, I. Changing paradigms in detecting rare adverse drug reactions: From disproportionality analysis, old and new, to machine learning. Expert Opin. Drug Saf. 21, 1235\u20131238. https:\/\/doi.org\/10.1080\/14740338.2022.2131770 (2022).","journal-title":"Expert Opin. Drug Saf."},{"key":"26340_CR12","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1093\/jjco\/hyac024","volume":"52","author":"Y Ohe","year":"2022","unstructured":"Ohe, Y. et al. The real-world safety of atezolizumab as second-line or later treatment in Japanese patients with non-small-cell lung cancer: A post-marketing surveillance study. Jpn. J. Clin. Oncol. 52, 623\u2013632. https:\/\/doi.org\/10.1093\/jjco\/hyac024 (2022).","journal-title":"Jpn. J. Clin. Oncol."},{"key":"26340_CR13","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.jsps.2022.06.010","volume":"30","author":"EA Alghamdi","year":"2022","unstructured":"Alghamdi, E. A., Aljohani, H., Alghamdi, W. & Alharbi, F. Immune checkpoint inhibitors and potential risk of thromboembolic events: Analysis of the WHO global database of individual case safety reports. Saudi Pharm. J. 30, 1193\u20131199. https:\/\/doi.org\/10.1016\/j.jsps.2022.06.010 (2022).","journal-title":"Saudi Pharm. J."},{"key":"26340_CR14","doi-asserted-by":"publisher","first-page":"830","DOI":"10.3389\/fphar.2020.00830","volume":"11","author":"R Ruggiero","year":"2020","unstructured":"Ruggiero, R. et al. Immune checkpoint inhibitors and immune-related adverse drug reactions: Data from Italian pharmacovigilance database. Front. Pharmacol. 11, 830. https:\/\/doi.org\/10.3389\/fphar.2020.00830 (2020).","journal-title":"Front. Pharmacol."},{"key":"26340_CR15","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s40264-015-0388-3","volume":"39","author":"S Seabroke","year":"2016","unstructured":"Seabroke, S. et al. Performance of stratified and subgrouped disproportionality analyses in spontaneous databases. Drug Saf. 39, 355\u2013364. https:\/\/doi.org\/10.1007\/s40264-015-0388-3 (2016).","journal-title":"Drug Saf."},{"key":"26340_CR16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jclinepi.2021.01.015","volume":"134","author":"C Khouri","year":"2021","unstructured":"Khouri, C. et al. Adverse drug reaction risks obtained from meta-analyses and pharmacovigilance disproportionality analyses are correlated in most cases. J. Clin. Epidemiol. 134, 14\u201321. https:\/\/doi.org\/10.1016\/j.jclinepi.2021.01.015 (2021).","journal-title":"J. Clin. Epidemiol."},{"key":"26340_CR17","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman, K. J., Lanes, S. & Sacks, S. T. The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol. Drug Saf. 13, 519\u2013523. https:\/\/doi.org\/10.1002\/pds.1001 (2004).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"26340_CR18","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans, S. J., Waller, P. C. & Davis, S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol. Drug Saf. 10, 483\u2013486. https:\/\/doi.org\/10.1002\/pds.677 (2001).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"26340_CR19","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate, A. et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur. J. Clin. Pharmacol. 54, 315\u2013321. https:\/\/doi.org\/10.1007\/s002280050466 (1998).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"26340_CR20","doi-asserted-by":"publisher","first-page":"875","DOI":"10.2165\/00002018-200629100-00005","volume":"29","author":"JS Almenoff","year":"2006","unstructured":"Almenoff, J. S., LaCroix, K. K., Yuen, N. A., Fram, D. & DuMouchel, W. Comparative performance of two quantitative safety signalling methods: Implications for use in a pharmacovigilance department. Drug Saf. 29, 875\u2013887. https:\/\/doi.org\/10.2165\/00002018-200629100-00005 (2006).","journal-title":"Drug Saf."},{"key":"26340_CR21","doi-asserted-by":"publisher","first-page":"1382441","DOI":"10.3389\/fphar.2024.1382441","volume":"15","author":"J Wu","year":"2024","unstructured":"Wu, J., Pan, H., Shen, L. & Zhao, M. Assessing the safety of bedaquiline: Insight from adverse event reporting system analysis. Front. Pharmacol. 15, 1382441. https:\/\/doi.org\/10.3389\/fphar.2024.1382441 (2024).","journal-title":"Front. Pharmacol."},{"key":"26340_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107924","volume":"196","author":"M Reck","year":"2024","unstructured":"Reck, M. et al. Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study. Lung Cancer 196, 107924. https:\/\/doi.org\/10.1016\/j.lungcan.2024.107924 (2024).","journal-title":"Lung Cancer"},{"key":"26340_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101393","volume":"5","author":"MD Galsky","year":"2024","unstructured":"Galsky, M. D. et al. Immunomodulatory effects and improved outcomes with cisplatin- versus carboplatin-based chemotherapy plus atezolizumab in urothelial cancer. Cell Rep. Med. 5, 101393. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101393 (2024).","journal-title":"Cell Rep. Med."},{"key":"26340_CR24","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S1470-2045(19)30167-6","volume":"20","author":"H West","year":"2019","unstructured":"West, H. et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): A multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 20, 924\u2013937. https:\/\/doi.org\/10.1016\/S1470-2045(19)30167-6 (2019).","journal-title":"Lancet Oncol."},{"key":"26340_CR25","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14830","volume":"34","author":"P Cutroneo","year":"2021","unstructured":"Cutroneo, P. et al. Psoriasis and psoriasiform reactions secondary to immune checkpoint inhibitors. Dermatol. Ther. 34, e14830. https:\/\/doi.org\/10.1111\/dth.14830 (2021).","journal-title":"Dermatol. Ther."},{"key":"26340_CR26","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1038\/s41598-025-85831-4","volume":"15","author":"H Wang","year":"2025","unstructured":"Wang, H., Li, J., Zhu, X., Wang, R. & Wan, Y. A real-world drug safety surveillance study from the FAERS database of hepatocellular carcinoma patients receiving pembrolizumab alone and plus lenvatinib. Sci. Rep. 15, 1425. https:\/\/doi.org\/10.1038\/s41598-025-85831-4 (2025).","journal-title":"Sci. Rep."},{"key":"26340_CR27","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41581-023-00787-w","volume":"20","author":"SE Dunn","year":"2024","unstructured":"Dunn, S. E., Perry, W. A. & Klein, S. L. Mechanisms and consequences of sex differences in immune responses. Nat. Rev. Nephrol. 20, 37\u201355. https:\/\/doi.org\/10.1038\/s41581-023-00787-w (2024).","journal-title":"Nat. Rev. Nephrol."},{"key":"26340_CR28","doi-asserted-by":"publisher","first-page":"4603","DOI":"10.1158\/1078-0432.CCR-19-0137","volume":"25","author":"BC Ozdemir","year":"2019","unstructured":"Ozdemir, B. C. & Dotto, G. P. Sex hormones and anticancer immunity. Clin. Cancer Res. 25, 4603\u20134610. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-0137 (2019).","journal-title":"Clin. Cancer Res."},{"key":"26340_CR29","doi-asserted-by":"publisher","first-page":"891179","DOI":"10.3389\/fmed.2022.891179","volume":"9","author":"M Sabate Gallego","year":"2022","unstructured":"Sabate Gallego, M. et al. Incidence and characteristics of adverse drug reactions in a cohort of patients treated with PD-1\/PD-L1 inhibitors in real-world practice. Front. Med. Lausanne 9, 891179. https:\/\/doi.org\/10.3389\/fmed.2022.891179 (2022).","journal-title":"Front. Med. Lausanne"},{"key":"26340_CR30","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-071079","volume":"13","author":"O Menang","year":"2023","unstructured":"Menang, O., Kuemmerle, A., Maigetter, K. & Burri, C. Strategies and interventions to strengthen pharmacovigilance systems in low-income and middle-income countries: A scoping review. BMJ Open 13, e071079. https:\/\/doi.org\/10.1136\/bmjopen-2022-071079 (2023).","journal-title":"BMJ Open"},{"key":"26340_CR31","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/pds.4111","volume":"26","author":"K Jayaputra","year":"2017","unstructured":"Jayaputra, K. & Ono, S. Differences between the United States and Japan in labels of oncological drugs. Pharmacoepidemiol. Drug Saf 26, 143\u2013151. https:\/\/doi.org\/10.1002\/pds.4111 (2017).","journal-title":"Pharmacoepidemiol. Drug Saf"},{"key":"26340_CR32","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/s41598-020-79397-6","volume":"11","author":"R Matsukane","year":"2021","unstructured":"Matsukane, R. et al. Continuous monitoring of neutrophils to lymphocytes ratio for estimating the onset, severity, and subsequent prognosis of immune related adverse events. Sci. Rep. 11, 1324. https:\/\/doi.org\/10.1038\/s41598-020-79397-6 (2021).","journal-title":"Sci. Rep."},{"key":"26340_CR33","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1148\/rg.2019190036","volume":"39","author":"KR Kalisz","year":"2019","unstructured":"Kalisz, K. R., Ramaiya, N. H., Laukamp, K. R. & Gupta, A. Immune checkpoint inhibitor therapy-related pneumonitis: Patterns and management. Radiographics 39, 1923\u20131937. https:\/\/doi.org\/10.1148\/rg.2019190036 (2019).","journal-title":"Radiographics"},{"key":"26340_CR34","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1159\/000531182","volume":"13","author":"YS Song","year":"2024","unstructured":"Song, Y. S. et al. Thyroid dysfunction after atezolizumab and bevacizumab is associated with favorable outcomes in hepatocellular carcinoma. Liver Cancer 13, 89\u201398. https:\/\/doi.org\/10.1159\/000531182 (2024).","journal-title":"Liver Cancer"},{"key":"26340_CR35","doi-asserted-by":"publisher","first-page":"2050313X2311644","DOI":"10.1177\/2050313X231164488","volume":"11","author":"T Ichimura","year":"2023","unstructured":"Ichimura, T., Ichikura, D., Hinata, M., Hida, N. & Baba, T. Thyroid dysfunction with atezolizumab plus bevacizumab after lenvatinib in hepatocellular carcinoma: A case series. SAGE Open Med. Case Rep. 11, 2050313X231164488. https:\/\/doi.org\/10.1177\/2050313X231164488 (2023).","journal-title":"SAGE Open Med. Case Rep."},{"key":"26340_CR36","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1053\/j.seminoncol.2023.11.003","volume":"50","author":"S Martella","year":"2023","unstructured":"Martella, S. et al. Primary adrenal insufficiency induced by immune checkpoint inhibitors: Biological, clinical, and radiological aspects. Semin. Oncol. 50, 144\u2013148. https:\/\/doi.org\/10.1053\/j.seminoncol.2023.11.003 (2023).","journal-title":"Semin. Oncol."},{"key":"26340_CR37","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1530\/EJE-19-0291","volume":"181","author":"JMK de Filette","year":"2019","unstructured":"de Filette, J. M. K. et al. Immune checkpoint inhibitors and type 1 diabetes mellitus: A case report and systematic review. Eur. J. Endocrinol. 181, 363\u2013374. https:\/\/doi.org\/10.1530\/EJE-19-0291 (2019).","journal-title":"Eur. J. Endocrinol."},{"key":"26340_CR38","doi-asserted-by":"publisher","first-page":"1084441","DOI":"10.3389\/fendo.2022.1084441","volume":"13","author":"W Zhang","year":"2022","unstructured":"Zhang, W. et al. Combined diabetic ketoacidosis and hyperosmolar hyperglycemic state in type 1 diabetes mellitus induced by immune checkpoint inhibitors: Underrecognized and underreported emergency in ICIs-DM. Front. Endocrinol. Lausanne 13, 1084441. https:\/\/doi.org\/10.3389\/fendo.2022.1084441 (2022).","journal-title":"Front. Endocrinol. Lausanne"},{"key":"26340_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241411694","author":"Y Endo","year":"2023","unstructured":"Endo, Y., Winarski, K. L., Sajib, M. S., Ju, A. & Wu, W. J. Atezolizumab induces necroptosis and contributes to hepatotoxicity of human hepatocytes. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms241411694 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"26340_CR40","doi-asserted-by":"publisher","first-page":"523","DOI":"10.2147\/DDDT.S188893","volume":"13","author":"Y Tie","year":"2019","unstructured":"Tie, Y. et al. Safety and efficacy of atezolizumab in the treatment of cancers: A systematic review and pooled-analysis. Drug Des. Dev. Ther. 13, 523\u2013538. https:\/\/doi.org\/10.2147\/DDDT.S188893 (2019).","journal-title":"Drug Des. Dev. Ther."},{"key":"26340_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/rcr2.1324","volume":"12","author":"D Jingu","year":"2024","unstructured":"Jingu, D. et al. Atezolizumab-related sclerosing cholangitis with multiple liver abscesses in a patient with lung squamous cell carcinoma: A case report. Respirol. Case Rep. 12, e01324. https:\/\/doi.org\/10.1002\/rcr2.1324 (2024).","journal-title":"Respirol. Case Rep."},{"key":"26340_CR42","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s00228-024-03647-z","volume":"80","author":"C Oliveira","year":"2024","unstructured":"Oliveira, C. et al. Immune-related serious adverse events with immune checkpoint inhibitors: Systematic review and network meta-analysis. Eur. J. Clin. Pharmacol. 80, 677\u2013684. https:\/\/doi.org\/10.1007\/s00228-024-03647-z (2024).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"26340_CR43","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s40264-021-01082-y","volume":"44","author":"J Setyawan","year":"2021","unstructured":"Setyawan, J., Azimi, N., Strand, V., Yarur, A. & Fridman, M. Reporting of thromboembolic events with JAK inhibitors: Analysis of the FAERS database 2010\u20132019. Drug Saf. 44, 889\u2013897. https:\/\/doi.org\/10.1007\/s40264-021-01082-y (2021).","journal-title":"Drug Saf."},{"key":"26340_CR44","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-024-03644-9","author":"Y Lu","year":"2024","unstructured":"Lu, Y. & Lu, Y. Clinical predictive factors of the efficacy of immune checkpoint inhibitors and kinase inhibitors in advanced hepatocellular cancer. Clin. Transl. Oncol. https:\/\/doi.org\/10.1007\/s12094-024-03644-9 (2024).","journal-title":"Clin. Transl. Oncol."},{"key":"26340_CR45","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/ejh.13734","volume":"108","author":"A Goel","year":"2022","unstructured":"Goel, A. et al. Assessing the risk of thromboembolism in cancer patients receiving immunotherapy. Eur. J. Haematol. 108, 271\u2013277. https:\/\/doi.org\/10.1111\/ejh.13734 (2022).","journal-title":"Eur. J. Haematol."},{"key":"26340_CR46","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00262-024-03850-y","volume":"74","author":"M Beckmann","year":"2024","unstructured":"Beckmann, M. et al. Interdependence of coagulation with immunotherapy and BRAF\/MEK inhibitor therapy: Results from a prospective study. Cancer Immunol. Immunother. 74, 5. https:\/\/doi.org\/10.1007\/s00262-024-03850-y (2024).","journal-title":"Cancer Immunol. Immunother."},{"key":"26340_CR47","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1001\/jamaneurol.2021.0249","volume":"78","author":"R Velasco","year":"2021","unstructured":"Velasco, R. et al. encephalitis induced by immune checkpoint inhibitors: A systematic review. JAMA Neurol. 78, 864\u2013873. https:\/\/doi.org\/10.1001\/jamaneurol.2021.0249 (2021).","journal-title":"JAMA Neurol."},{"key":"26340_CR48","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1212\/WNL.0000000000011795","volume":"96","author":"A Marini","year":"2021","unstructured":"Marini, A. et al. Neurologic adverse events of immune checkpoint inhibitors: A systematic review. Neurology 96, 754\u2013766. https:\/\/doi.org\/10.1212\/WNL.0000000000011795 (2021).","journal-title":"Neurology"},{"key":"26340_CR49","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1002\/onco.13931","volume":"26","author":"R Pathak","year":"2021","unstructured":"Pathak, R. et al. Immune checkpoint inhibitor-induced myocarditis with myositis\/myasthenia gravis overlap syndrome: A systematic review of cases. Oncologist 26, 1052\u20131061. https:\/\/doi.org\/10.1002\/onco.13931 (2021).","journal-title":"Oncologist"},{"key":"26340_CR50","doi-asserted-by":"publisher","first-page":"24561","DOI":"10.1038\/s41598-024-74729-2","volume":"14","author":"YD Jeong","year":"2024","unstructured":"Jeong, Y. D. et al. Global burden of vaccine-associated Guillain-Barre syndrome over 170 countries from 1967 to 2023. Sci. Rep. 14, 24561. https:\/\/doi.org\/10.1038\/s41598-024-74729-2 (2024).","journal-title":"Sci. Rep."},{"key":"26340_CR51","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1007\/s00415-021-10404-0","volume":"268","author":"Q Fan","year":"2021","unstructured":"Fan, Q., Hu, Y., Wang, X. & Zhao, B. Guillain-Barre syndrome in patients treated with immune checkpoint inhibitors. J. Neurol. 268, 2169\u20132174. https:\/\/doi.org\/10.1007\/s00415-021-10404-0 (2021).","journal-title":"J. Neurol."},{"key":"26340_CR52","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli, M. et al. The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance (READUS-PV): Development and statement. Drug Saf. 47, 575\u2013584. https:\/\/doi.org\/10.1007\/s40264-024-01421-9 (2024).","journal-title":"Drug Saf."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26340-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26340-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26340-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T13:35:51Z","timestamp":1764164151000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-26340-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["26340"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-26340-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"assertion":[{"value":"16 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"42218"}}